

#### MONOCLONAL ANTIBODY

For research use only, Not for diagnostic use.

# Catalog No.LKG-M010

# **Anti-Mouse LYVE-1 [Clone: 64R]**

#### BACKGROUND

Cancer metastasis is associated with poor prognosis and accounts for the majority of cancer-related death<sup>1,2)</sup>. There are two major mechanisms by which cancer metastasis occurs: hematogenous and lymphogenous metastasis<sup>3)</sup>. The lymphatic route has been shown to be more important as an initial route for the spread of cancer than the hematogenous route<sup>4,5)</sup>, especially for carcinomas. Accordingly, metastatic spread to lymph nodes (LN) is regarded as a prognostic indicator<sup>6)</sup>.

Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is a homolog of cluster of differentiation (CD) 44, a receptor for hyaluronan expressed on lymphatic endothelial cells (LEC)<sup>7,8)</sup>, and is utilized as a lymphatic-specific marker. LYVE-1 binds to hyaluronan, and is involved in the migration of LEC<sup>9)</sup>. Furthermore, LYVE-1 promotes hyaluronan-induced lymphangiogenesis<sup>9,10)</sup>. In clinical studies, LYVE-1 proteins were significantly increased in colon tumors compared with in unaffected colon tissues<sup>11)</sup>. LYVE-1 gene expression was upregulated in muscle-invasive bladder cancers exhibiting positive lympho-vascular invasion and LN metastasis compared with in non-muscle invasive bladder cancers<sup>12)</sup>. Thus, LYVE-1 is involved in primary tumor formation and metastasis, and it is expected to be useful for cancer treatment target.

This anti-LYVE-1 antibody (38M) specifically stain lymphatic vessels in several mouse tissues on immunohistology<sup>13</sup>. It has been developed by Cell Biology Laboratory, Kindai University (Prof. T. Masuko).

**Product type** Primary Antibodies

Immunogen Mouse LYVE-1 transfected cell

Raised in Rat

Myeloma  $P3 \times 63Ag8.653$ 

Clone number 64R

Isotype IgG2a/κ
Source Ascites

**Purification** Caprylic acid clearance and ammonium sulphate precipitation

Buffer 0.9 % NaCl\*

\*NOTE: This solution doesn't contain preservative. Preservative is added based on the research purpose.

**Concentration** 1 mg/mL

Volume 100 μL (100 μg)
Label Unlabeled

**Specificity** Mouse LYVE-1 extracellular domain

64R has no reactivity to mouse CD44 (the closest homologue of LYVE-1).

Cross reactivity Mouse, No-cross reaction with rat or human, Other species are not tested.

**Storage** Store cold (2 to 8 °C)

**Application notes** Flow cytomerty; 10 μg/mL

Recommended Tube formation assay;  $10 \mu g/mL$  Wound healing assay;  $10 \mu g/mL$ 

dilutions Immunohistochemistry (frozen); 10 µg/mL

:38M (related product) is recommended for immunohistochemistry.

Immunoprecipitation

- Other applications have not been tested.


- Optimal dilutions/concentrations should be determined by the end user.

#### References

- Mehlen P., et al., Nat Rev Cancer. 2006 Jun;6(6):449-58. PMID: 16723991 1)
- 2) Nguyen DX., et al., Nat Rev Cancer. 2009 Apr;9(4):274-84. PMID: 19308067
- 3) Wong SY., et al., Cell Cycle. 2006 Apr;5(8):812-7. PMID: 16627996
- 4) Clarijs R., et al., J Pathol. 2001 Feb;193(2):143-6. PMID: 11180158
- 5) Pepper MS., et al., Clin Cancer Res. 2001 Mar;7(3):462-8. PMID: 11297234
- 6) Stacker SA., et al., FASEB J. 2002 Jul;16(9):922-34. PMID: 12087053
- 7) Banerji S., et al., J Cell Biol. 1999 Feb 22;144(4):789-801. PMID: 10037799
- 8) Prevo R., et al., J Biol Chem. 2001 Jun 1;276(22):19420-30. PMID: 11278811
- 9) Wu M., et al., PLoS One. 2014 Mar 25;9(3):e92857. PMID: 24667755
- 10) Yu M., et al., Exp Cell Res. 2015 Aug 1;336(1):150-7. PMID: 26116468
- 11) Langenes V., et al., Cancer Immunol Immunother. 2013 Nov;62(11):1687-95. PMID: 24013383
- 12) Poyet C., et al., Oncotarget. 2017 Mar 28;8(13):21871-21883. PMID: 28423532
- 13) Hara Y., et al., Cancer Sci. 2018 Oct;109(10):3171-3182. PMID: 30058195


# **Application data**

# ◆ Flow cytometry (FCM)



Flow cytometry analysis of mouse LYVE-1 in Primary mouse lymphatic endothelial cells (LEC) and SVEC4-10 LEC line with anti-LYVE-1 (64R, 10 µg/mL) antibody and PE-labeled anti Rat IgG antibody.


# ◆ Flow cytometry (FCM) **GFP-mouse LYVE-1** / HEK293



Expressopm of GFP-fused protein

Flow cytometry analysis of antigenic specificity using mouse LYVE-1 expressing cells with anti-LYVE-1 (64R, 10 µg/mL) antibody and PE-labeled anti Rat IgG antibody. Specific response against GFP-fused mouse LYVE-1 protein by anti-LYVE-1 antibody was observed in a GFP intensity-dependent manner.

# ◆ Immunohistochemistry (Frozen) Mouse axillary lymph nodesh




Immunohistochemistry staining mouse axillary lymph nodes with anti-LYVE-1 antibody (64R, 10 µg/mL). Nuclei were counterstained with methyl green.

38M (related product) is recommended for immunohistochemistry, given that the immunostaining signal of 64R is weaker than those of 38M.

#### **Application data**


# ◆ Tube formation assay



SVEC4-10 cells were plated onto Matrigel-coated chambers, added with or without anti-LYVE-1 antibody (64R, 10  $\mu$ g/mL). Three hours after incubation at 37°C, images were taken using a microscope.

# ◆ Wound healing assay

A: GFP-mouse LYVE-1 / HEK293



A: Representative images of wounds in HEK293 cells expressing mouse LYVE-1-GFP cell culture before and 8 hours after treatment with 64R. B: Representative images of wounds in SVEC4-10 cell culture before and 12 hours after treatment with 64R. Broken lines, wound edge.

# **PROTOCOLS:**

## Flow cytometry (Cell Analyzing)

### A. Cell Preparation

- 1. Remove cells from incubator.
- 2. Discard culture medium.
- 3. Briefly rinse the cell layer with PBS.
- 4. Add 0.25 % trypsin-EDTA solution to dish. Return the dish to the incubator and incubate for 2-10 minutes or until cells are detached.
- 5. Resuspend cells in complete growth medium with 10% FBS to inactivate the trypsin.

#### B. Staining

- 1. Aliquot 1x10<sup>5</sup> cells into each assay tube.
- 2. Add 150  $\mu$ l 0.2 % BSA in PBS to each tube and rinse by centrifugation.
- 3. Add 50 µl diluted primary antibody (10 µg/ml 64R in 0.2 % BSA in PBS) to the assay tubes.
- 4. Incubate for one hour at 4 °C.
- 5. Add 100 μl 0.1 % BSA in PBS to each tube and wash by centrifugation.
- 6. Wash two times in 150  $\mu$ l 0.1 % BSA in PBS by centrifugation.
- Resuspend cells in 50 μl PE-labeled secondary antibody solution (Jackson Immuno Research 712-116-153), diluted 1:200 in 0.1 % BSA in PBS.
- 8. Incubate for 30 minutes at 4 °C in the dark.
- 9. Add 100 μl 0.1 % BSA in PBS to each tube and wash by centrifugation.
- 10. Wash two times in 150 μl 0.1 % BSA in PBS by centrifugation
- 11. Resuspend cells in 100 µl PBS.
- 12. Analyze using flow cytometry.

## **PROTOCOLS:**

## **Tube formation assay**

## A. Preparation of Matrigel-Coated slide chamber

- 1. Thaw Matrigel matrix (Corning, Corning, NY, USA) by submerging the vial in a 4°C refrigerator overnight before use.
- 2. Add Matrigel matrix to each well (100 μL) of an 8-well slide chamber (WATSON Bio Lab, Kobe, Japan), spread evenly with a pipet tip, and allow to solidify at 37°C for 30 minutes.

#### B. Cell Preparation

- 1. Remove lymphatic endothelial cells (LEC) from incubator.
- 2. Discard culture medium.
- 3. Briefly rinse the cell layer with PBS.
- 4. Trypsinize the cells to make a single-cell suspension, and then pellet the cells through centrifugation at 125 x g for 5 minutes at room temperature.
- 5. Re-suspend cells in complete growth medium with supernatants from MDA-MB-231-luc-LN cells.

## C. Cell culture on Matrigel-Coated slide chamber

- 1. Plate cells onto Matrigel-coated chambers ( $5\times10^4$  cells), added with or without anti-LYVE-1 antibody (64R,  $10 \mu g/mL$ ). Note: The number of cells may need optimization depending on the growth properties of the cell line.
- 2. Incubate in humidified CO<sub>2</sub> incubators for 3 hours.
  - Note: Incubation time may need optimization depending on the cell properties.
- 3. Observe cells under a microscope.

# Wound healing assay

- 1. Plate cells onto tissue culture plate.
- 2. Make scratch wounds by scraping the cell layer with a micropipette tip, when the cells neared 100 % confluent.
- 3. After scratching, gently wash the well twice with medium to remove the detached cells.
- 4. Replenish the well with fresh medium with Supernatants from MDA-MB-231-luc-LN cells, added with or without anti-LYVE-1 antibody (64R, 10 μg/mL).
- 5. Incubate in humidified CO<sub>2</sub> incubators for 12 hours.
  - Note: Incubation time may need optimization depending on the cell properties.
- 6. Observe scratch wound under a microscope.

## RELATED PRODUCT

Product Name	Clone	Application	Quantity	Maker	Cat#
Anti Mouse LYVE-1	38M	FCM/IHC/IP	100 μg / 100 μL	CAC	LKG-M009

For research use only, Not for diagnostic use.



COSMO BIO CO., LTD.

(JAPAN)

TOYO EKIMAE BLDG. 2-20, TOYO 2-CHOME, KOTO-KU. TOKYO 135-0016, JAPAN Phone: +81-3-5632-9610 FAX: +81-3-5632-9619

FAX: +81-3-5632-9619 URL: https://www.cosmobio.co.jp/



COSMO BIO USA

[Outside Japan] 2792 Loker Ave West, Suite 101 Carlsbad, CA 92010, USA email: info@cosmobiousa.com Phone/FAX: (+1) 760-431-4600 URL: www.cosmobiousa.com